Abstract
SLC17A1 protein (NPT1) was the first identified member of the SLC17 phosphate transporter family, and is known to mediate Na+/inorganic phosphate (Pi) co-transport when expressed in Xenopus oocytes. Although this protein was suggested to be a renal polyspecific anion exporter, its transport properties were not well characterized. The clean biochemical approach revealed that proteoliposomes comprising purified NPT1 as the only protein source transport various organic anions such as urate, p-aminohippuric acid (PAH), and acetylsalicylic acid (aspirin) in a membrane potential (Δψ)-driven and Cl- -dependent manner. Human NPT1 carrying an SNP mutation, Thr269Ile, known to increase the risk of gout, exhibited 32% lower urate transport activity compared to the wild type protein, leading to the conclusion that NPT1 is the long searched for transporter responsible for renal urate excretion. In the present article, we summarized the history of identification of the urate exporter and its possible involvement in the dynamism of urate under physiological and pathological conditions.
Keywords: Drug excretion, gout, membrane potential, Na+/inorganic phosphate transporter, non-steroidal anti-inflammatory drug, urate.
Current Molecular Pharmacology
Title:Type 1 Sodium-Dependent Phosphate Transporter acts as a Membrane Potential-Driven Urate Exporter
Volume: 6
Author(s): Takaaki Miyaji, Tatsuya Kawasaki, Natsuko Togawa, Hiroshi Omote and Yoshinori Moriyama
Affiliation:
Keywords: Drug excretion, gout, membrane potential, Na+/inorganic phosphate transporter, non-steroidal anti-inflammatory drug, urate.
Abstract: SLC17A1 protein (NPT1) was the first identified member of the SLC17 phosphate transporter family, and is known to mediate Na+/inorganic phosphate (Pi) co-transport when expressed in Xenopus oocytes. Although this protein was suggested to be a renal polyspecific anion exporter, its transport properties were not well characterized. The clean biochemical approach revealed that proteoliposomes comprising purified NPT1 as the only protein source transport various organic anions such as urate, p-aminohippuric acid (PAH), and acetylsalicylic acid (aspirin) in a membrane potential (Δψ)-driven and Cl- -dependent manner. Human NPT1 carrying an SNP mutation, Thr269Ile, known to increase the risk of gout, exhibited 32% lower urate transport activity compared to the wild type protein, leading to the conclusion that NPT1 is the long searched for transporter responsible for renal urate excretion. In the present article, we summarized the history of identification of the urate exporter and its possible involvement in the dynamism of urate under physiological and pathological conditions.
Export Options
About this article
Cite this article as:
Miyaji Takaaki, Kawasaki Tatsuya, Togawa Natsuko, Omote Hiroshi and Moriyama Yoshinori, Type 1 Sodium-Dependent Phosphate Transporter acts as a Membrane Potential-Driven Urate Exporter, Current Molecular Pharmacology 2013; 6 (2) . https://dx.doi.org/10.2174/18744672113069990035
DOI https://dx.doi.org/10.2174/18744672113069990035 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutrient-By-Genotype Interactions and Personalized Diet: What Can We Learn From Drosophila and Evolutionary Biology?
Current Pharmacogenomics and Personalized Medicine Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science Chymase Inhibitors
Current Pharmaceutical Design Neurovestibular and Sensorimotor Studies in Space and Earth Benefits
Current Pharmaceutical Biotechnology Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics Regulators of Platelet cAMP Levels: Clinical and Therapeutic Implications
Current Medicinal Chemistry Animal Peptides Targeting Voltage-Activated Sodium Channels
Current Pharmaceutical Design The Effects of Mesenchymal Stem Cells in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy Accuracy of Ultrasound Imaging Technique for Assessing Lipoatrophy in HIV-Infected Subjects
Current HIV Research CRIM1, the Antagonist of BMPs, is a Potential Risk Factor of Cancer
Current Cancer Drug Targets Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Therapy Of Cardiac Arrhythmias In Children: An Emerging Role Of Electroanatomical Mapping Systems
Current Vascular Pharmacology A Comparative Effectiveness Systematic Review and Meta-analysis of Drugs for the Prophylaxis of Junctional Ectopic Tachycardia
Current Cardiology Reviews Somatic Genome Variations in Health and Disease
Current Genomics Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Nanomedicine: Potential Devices for Diagnostics
Recent Patents on Nanomedicine An Update of Acyl-CoA: Cholesterol Acyltransferase Inhibition in Animal and Human In Vitro and In Vivo Models of Atherosclerosis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Policy and Health Implications of Using the U.S. Food and Drug Administration Product Design Approach in Reducing Tobacco Product Risk
Current Drug Abuse Reviews Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Current Cardiology Reviews Cartilage and Bone Extracellular Matrix
Current Pharmaceutical Design